Post-marketing safety evaluation of the live-attenuated chikungunya vaccine (IXCHIQ)

This publication has 12 references indexed in Scilit:

• More data needed on the FDA's decision to suspend Ixchiq
  The Lancet Infectious Diseases, 2025
• Fatal Adverse Event After VLA1553 Chikungunya Vaccination in an Elderly Patient: A Case Report From Reunion Island
  Open Forum Infectious Diseases, 2025
• Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine
  Journal of Travel Medicine, 2024
• Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study
  The Lancet Infectious Diseases, 2024
• Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine
  Journal of Travel Medicine, 2024
• Clinical outcomes of chikungunya: A systematic literature review and meta-analysis
  PLOS Neglected Tropical Diseases, 2024
• Pathophysiology of chikungunya virus infection associated with fatal outcomes
  Cell Host & Microbe, 2024
• A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults
  Journal of Travel Medicine, 2023
• Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
  The Lancet, 2023
• The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines
  PLOS Neglected Tropical Diseases, 2022